Veru, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.31%177.590.7%$1346.39m
MRKMerck & Co., Inc. 0.50%93.100.7%$1217.96m
PFEPfizer Inc. 0.70%52.000.9%$1102.81m
LLYEli Lilly & Co. 0.13%327.611.1%$1027.51m
BMYBristol-Myers Squibb Co. 0.15%76.071.0%$992.95m
ABBVAbbVie, Inc. -1.26%151.991.9%$948.13m
AZNAstraZeneca Plc 0.20%65.641.0%$471.89m
SGENSeagen Inc. -1.19%174.675.7%$322.19m
GSKGSK Plc -0.97%42.880.2%$269.75m
TPTXTurning Point Therapeutics, Inc. -0.19%75.010.0%$198.91m
HZNPHorizon Therapeutics Plc -0.86%82.055.4%$172.59m
NVSNovartis AG -1.29%83.200.2%$170.06m
ALNYAlnylam Pharmaceuticals, Inc. 0.27%151.148.1%$150.72m
MRTXMirati Therapeutics, Inc. -1.14%71.141.6%$149.09m
NVONovo Nordisk A/S -0.76%110.390.1%$147.23m

Company Profile

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.